Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up

A. Zinchenko (St. Petersburg, Russian Federation), L. Novikova (St. Petersburg, Russian Federation), M. Ilkovich (St. Petersburg, Russian Federation)

Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Zinchenko (St. Petersburg, Russian Federation), L. Novikova (St. Petersburg, Russian Federation), M. Ilkovich (St. Petersburg, Russian Federation). Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up. 3405

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019



Chemotherapy in patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018



Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis
Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017
Year: 2018



Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019

Multisystemic Langerhans cell histiocytosis unresponsive to aggressive chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 383s
Year: 2006

Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012

Clinical course and outcome of pulmonary Langerhans‘-cell histiocytosis
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010

Cladribine improves lung cysts and pulmonary function in a child with histiocytosis
Source: Eur Respir J 2015; 45: 831-833
Year: 2015


Exercise in patients with pulmonary Langerhans cell histiocytosis: performance and mechanisms of limitation
Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases
Year: 2017




Langerhans' cell histiocytosis: clinical and diagnostic features and response to therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 219s
Year: 2001

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients
Source: Eur Respir Rev 2013; 22: 93-95
Year: 2013


Pneumothorax in patients with Langerhans cell histiocytosis
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017

Long-term follow-up of patients with pulmonary sarcoidosis
Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Year: 2018


Cladribine as a second line treatment in a child with isolated pulmonary Langerhans cell histiocytosis – case report
Source: International Congress 2018 – Orphan diseases in children
Year: 2018



Treatment of pulmonary Langerhans cell histiocytosis with multifocal involvement with vinblastine, prednisolon, mercaptopurine
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010


How I manage pulmonary Langerhans cell histiocytosis
Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017
Year: 2017



Smoking status and long term clinical outcome in patients with pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013


Psychological abnormalities are commonly present in adult patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019


Paediatric pulmonary Langerhans cell histiocytosis
Source: Breathe, 16 (2) 200003; 10.1183/20734735.0003-2020
Year: 2020



Lung transplantation for pulmonary Langerhans‘ cell histiocytosis
Source: Eur Respir J 2005; 26: Suppl. 49, 635s
Year: 2005